DI-Leu16-IL2(DI-Leu16-IL2) - 药物靶点：CD20 x IL-2R_在研适应症：非霍奇金淋巴瘤，血液肿瘤_专利_临床

概要

基本信息

药物类型

融合蛋白

别名

Anti-CD20 monoclonal antibody-interleukin-2 fusion protein、DI-Leu16-IL2 immunocytokine、de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2

+ [1]

靶点

CD20 x IL-2R

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、IL-2R激动剂(白细胞介素-2受体复合体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Provenance Biopharmaceuticals Corp.Merck Serono SA

非在研机构

Alopexx Oncology, LLC

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 16279555VH

Sequence Code 14671992VL

关联

2

项与 DI-Leu16-IL2 相关的临床试验

NCT02151903 / Terminated临床1/2期

An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)

This is an open-label extension study enrolling participants experiencing clinical benefit following 6 cycles of DI-Leu16-IL2 while enrolled in the Alopexx Oncology Dose-Escalation AO-101 study (NCT01874288). Participants will be permitted to continue to receive DI-Leu16-IL2 at the same dose, schedule, and route of administration they received during Study AO-101 (Main Study). Prior pre-treatment (for example, Rituximab) will continue as before.

开始日期2014-11-04

申办/合作机构

Alopexx Oncology, LLC

NCT01874288 / Terminated临床1/2期

A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)

This dose-escalation study is designed for determining the safety, tolerability, pharmacokinetics (PK), biological, and clinical activity of DI-Leu16-IL2 administered to participants with cluster of differentiation 20 (CD20) positive NHL that have failed standard rituximab-containing therapy.

开始日期2013-11-25

申办/合作机构

Alopexx Oncology, LLC

100 项与 DI-Leu16-IL2 相关的临床结果

登录后查看更多信息

100 项与 DI-Leu16-IL2 相关的转化医学

登录后查看更多信息

100 项与 DI-Leu16-IL2 相关的专利（医药）

登录后查看更多信息

4

项与 DI-Leu16-IL2 相关的文献（医药）

2015-07-01·Clinical Lymphoma Myeloma and Leukemia4区 · 医学

Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice

4区 · 医学

Review

作者: Burger, Jan A ; Wierda, William G ; Sanford, David S ; O'Brien, Susan M ; Keating, Michael J

Three agents have received Food and Drug Administration (FDA) approval for treatment of chronic lymphocytic leukemia (CLL) within the past year. Ibrutinib and idelalisib block B-cell receptor signaling through inhibition of Bruton tyrosine kinase and phosphatidylinositol 3-kinase δ molecules respectively, interfering with several pathways required for leukemia cell survival. Idelalisib has shown efficacy in the relapsed setting and is currently approved by the FDA for use in combination with rituximab. Ibrutinib has been studied in patients with relapsed CLL and as frontline therapy. In the relapsed setting, these agents produce durable remissions, and might be preferable to re-treatment with chemoimmunotherapy for many patients. Ibrutinib is also effective treatment for patients with deletion 17p and is approved by the FDA as frontline therapy in this patient group, although it does not appear to completely abrogate this adverse prognostic factor. These agents have a unique side effect profile and longer follow-up is required to further understand tolerability and rare adverse effects. Obinutuzumab is a type-2 monoclonal anti-CD20 antibody which results in direct and antibody-dependent cell-mediated cytotoxicity of leukemia cells. It is approved by the FDA for use in combination with chlorambucil, and has shown efficacy in the frontline setting in patients unfit for more intensive chemoimmunotherapy. It produces increased response rates and minimal residual disease negativity compared with chlorambucil/rituximab and is associated with an advantage in progression-free survival but not yet overall survival. These agents underscore our advancement in the understanding of the biology of CLL and will improve outcomes for many patients with CLL.

2010-02-01·Current opinion in molecular therapeutics

TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis.

Review

作者: Rubbert-Roth, Andrea

TRU-015, being developed by Trubion Pharmaceuticals Inc and Pfizer Inc, is an intravenously administered anti-CD20 IgG fusion protein for the treatment of rheumatoid arthritis. TRU-015 depletes B-cells from the peripheral blood in vitro, and can mediate complement-and antibody-dependent cellular cytotoxicity. TRU-015 was well tolerated in patients with rheumatoid arthritis in phase I and II clinical trials, and demonstrated an efficacy profile similar to other biological agents approved for rheumatoid arthritis. At the time of publication, phase II trials were ongoing in patients with rheumatoid arthritis. TRU-015 could represent a novel therapy for the treatment of rheumatoid arthritis, although the efficacy, safety profile and advantages of this compound compared with existing therapeutic options would need to be established in phase III trials. In addition, this agent also may be useful to the treatment of B-cell neoplasms and autoimmune diseases.

2007-03-15·Cancer Research1区 · 医学

Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy

1区 · 医学

Article

作者: Forman, Stephen J. ; Serrano, Lisa Marie ; Singh, Harjeet ; McNamara, George ; Colcher, David ; Gillies, Stephen D. ; Olivares, Simon ; Jensen, Michael C. ; Raubitschek, Andrew ; Pfeiffer, Timothy ; Al-Kadhimi, Zaid ; Cooper, Laurence J.N. ; Smith, David D.

AbstractCurrently, the lineage-specific cell-surface molecules CD19 and CD20 present on many B-cell malignancies are targets for both antibody- and cell-based therapies. Coupling these two treatment modalities is predicted to improve the antitumor effect, particularly for tumors resistant to single-agent biotherapies. This can be shown using an immunocytokine, composed of a CD20-specific monoclonal antibody fused to biologically active interleukin 2 (IL-2), combined with ex vivo expanded human umbilical cord blood–derived CD8+ T cells, that have been genetically modified to be CD19 specific, for adoptive transfer after allogeneic hematopoietic stem-cell transplantation. We show that a benefit of targeted delivery of recombinant IL-2 by the immunocytokine to the CD19+CD20+ tumor microenvironment is improved in vivo persistence of the CD19-specific T cells, and this results in an augmented cell-mediated antitumor effect. Phase I trials are under way using anti-CD20-IL-2 immunocytokine and CD19-specific T cells as monotherapies, and our results warrant clinical trials using combination of these two immunotherapies. [Cancer Res 2007;67(6):2872–80]

100 项与 DI-Leu16-IL2 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非霍奇金淋巴瘤	临床2期	-	Merck Serono SA	-
非霍奇金淋巴瘤	临床2期	-	Provenance Biopharmaceuticals Corp.	-
B细胞淋巴瘤	临床前	美国	Alopexx Oncology, LLC	2013-11-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02151903 (CTgov)	临床1/2期	B细胞淋巴瘤	5	DI-Leu16-IL2 (DI-Leu16-IL2 1.0 mg/m^2)	(衊壓餘膚壓選製醖範糧) = 積蓋襯構築顧選憲鹽齋製築蓋廠遞築壓蓋餘襯 (壓廠糧觸窪壓膚製願壓, 蓋廠範淵繭艱淵繭鏇鑰 ~ 餘積糧簾糧範衊獵願齋) 更多	-	2020-11-27
				DI-Leu16-IL2 (DI-Leu16-IL2 2.0 mg/m^2)	(衊壓餘膚壓選製醖範糧) = 壓獵選憲壓獵憲醖憲膚製築蓋廠遞築壓蓋餘襯 (壓廠糧觸窪壓膚製願壓, 顧壓窪積窪壓繭鹽顧夢 ~ 餘壓選鬱壓鑰網齋艱鑰) 更多
NCT01874288 (CTgov)	临床1/2期	B细胞淋巴瘤	24	DI-Leu16-IL2 (DI-Leu16-IL2 0.5 mg/m^2)	餘鏇築網艱齋醖齋網構(餘構鹽襯顧繭廠網襯築) = 顧窪蓋糧鹹築憲製觸遞膚鏇選鏇鹽繭襯積鏇壓 (憲鏇廠繭積糧淵蓋築構, 醖夢築鑰艱壓網簾襯蓋 ~ 製壓顧壓醖餘製蓋繭餘) 更多	-	2020-11-24
				DI-Leu16-IL2 (DI-Leu16-IL2 1.0 mg/m^2)	餘鏇築網艱齋醖齋網構(餘構鹽襯顧繭廠網襯築) = 網願襯鑰齋艱鹹鬱糧醖膚鏇選鏇鹽繭襯積鏇壓 (憲鏇廠繭積糧淵蓋築構, 衊醖構選衊獵鏇顧淵壓 ~ 顧觸簾築網繭構艱膚蓋) 更多
NCT01874288 (ASCO2016)	临床1/2期	复发性B细胞淋巴瘤	18	DI-Leu16-IL2	襯夢齋衊願製鑰願壓窪(糧鏇選糧製廠壓襯襯選) = DLT occurred in 2 pts at 6 mg/m2 with delayed (8-10 days) grade 3 cytokine release syndrome, suggesting effector cell expansion as the cause. 壓壓憲選夢鹹醖鹹鹽鑰 (蓋餘構積願壓醖簾積遞 ) 更多	积极	2016-05-20